PTGS2 and myocardial infarction: Nevertheless, no major clinical trials of PTGS2 inhibitors were completed in CRC due to their adverse effects, such as elevated risk of myocardial infarction, dyspepsia, abdominal pain, gastrointestinal bleeding, and gastritis19,54.